Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers

被引:1
作者
Sakima, Atsushi [1 ,2 ]
Kita, Toshihiro [3 ]
Nakada, Seigo [4 ]
Yokota, Naoto [5 ]
Tamaki, Noboru [6 ]
Etoh, Takuma [7 ]
Shimokubo, Toru [8 ]
Kitamura, Kazuo [3 ]
Takishita, Shuichi [9 ]
Ohya, Yusuke [2 ]
机构
[1] Univ Ryukyus, Hlth Adm Ctr, Nishihara, Okinawa 9030213, Japan
[2] Univ Ryukyus, Dept Cardiovasc Med Nephrol & Neurol, Grad Sch Med, Nishihara, Okinawa 9030213, Japan
[3] Miyazaki Univ, Fac Med, Dept Internal Med, Div Circulatory & Body Fluid Regulat, Miyazaki, Japan
[4] Keiaikai Chibana Clin, Okinawa, Japan
[5] Yokota Naika, Miyazaki, Japan
[6] Tamaki Clin, Miyazaki, Japan
[7] Etoh Clin, Miyazaki, Japan
[8] Sakoda Hosp, Miyazaki, Japan
[9] Okinawa Coll Rehabil & Welf, Onna, Okinawa, Japan
关键词
Ambulatory blood pressure monitoring; angiotensin II receptor blocker; antihypertensive therapy; candesartan; diuretic; COMBINATION THERAPY; HEART-FAILURE; EFFICACY; VALSARTAN; SAFETY; ANTAGONISTS; GUIDELINES; MANAGEMENT; BLOCKADE; PLACEBO;
D O I
10.3109/10641963.2013.783052
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although blockade of the renin-angiotensin system by increasing the dose of angiotensin II receptor blockers (ARBs) is recommended to achieve clinical benefits in terms of blood pressure (BP) control and cardiovascular and renal outcomes, the effect of this increased dose on ambulatory BP monitoring has not been evaluated completely in Japanese patients with uncontrolled hypertension undergoing medium-dose ARB therapy. The primary objective of this study was to examine the effect of the relatively high dose of the ARB candesartan (12 mg/day) on 24-h systolic BP and the attainment of target BP levels in uncontrolled hypertension treated with a medium dose of ARBs. A total of 146 hypertensive patients (age: 69.9 +/- 9.3 years; females: 65.8%) completed the study. After switching to candesartan at 12 mg/day, all these BP measurements decreased significantly (p < 0.001). Attainment of the target office BP (p = 0.0014) and 24-h BP levels (p = 0.0296) also improved significantly. Subgroup analysis indicated that the reduction of 24-h systolic BP was larger in patients treated with diuretics than those without (p = 0.0206). Multivariate analysis revealed a significant correlation between the combined ARB and diuretic therapy, and the change in 24-h systolic BP irrespective of preceding ARBs. In conclusion, the switching therapy to increased dose of candesartan caused significant reductions in office and ambulatory BP levels, and improved the attainment of target BP levels in patients with uncontrolled hypertension treated with a medium dose of ARBs. Combination with diuretics enhanced this effect.
引用
收藏
页码:40 / 45
页数:6
相关论文
共 25 条
  • [1] Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension
    Birkenhäger, WH
    de Leeuw, PW
    [J]. JOURNAL OF HYPERTENSION, 1999, 17 (07) : 873 - 881
  • [2] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [3] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
    Cohn, JN
    Tognoni, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1667 - 1675
  • [4] Angiotensin II antagonists for hypertension: Are there differences in efficacy?
    Conlin, PR
    Spence, JD
    Williams, B
    Ribeiro, AB
    Saito, I
    Benedict, C
    Bunt, AMG
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2000, 13 (04) : 418 - 426
  • [5] Angiotensin II receptor blockade - Is there truly a benefit of adding an ACE inhibitor?
    Forclaz, A
    Maillard, M
    Nussberger, J
    Brunner, HR
    Burnier, M
    [J]. HYPERTENSION, 2003, 41 (01) : 31 - 36
  • [6] A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily Losartan 100 mg/hydrochlorothiazide 25 mg and Losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension
    Gradman, AH
    Brady, WE
    Gazdick, LP
    Lyle, P
    Zeldin, RK
    [J]. CLINICAL THERAPEUTICS, 2002, 24 (07) : 1049 - 1061
  • [7] Combination Therapy in Hypertension
    Gradman, Alan H.
    Basile, Jan N.
    Carter, Barry L.
    Bakris, George L.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (03) : 146 - 154
  • [8] Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study
    Hasebe, N
    Kikuchi, K
    [J]. JOURNAL OF HYPERTENSION, 2005, 23 (02) : 445 - 453
  • [9] Three-Year Safety and Effectiveness of Fixed-Dose Losartan/Hydrochlorothiazide Combination Therapy in Japanese Patients with Hypertension Under Clinical Setting (PALM-1 Extension Study)
    Kita, Toshihiro
    Yokota, Naoto
    Ichiki, Yoshinari
    Ayabe, Takao
    Etoh, Takuma
    Tamaki, Noboru
    Kato, Johji
    Eto, Tanenao
    Kitamura, Kazuo
    [J]. CLINICAL AND EXPERIMENTAL HYPERTENSION, 2012, 34 (07) : 498 - 503
  • [10] Increasing the doses of both diuretics and angiotensin receptor blockers is beneficial in subjects with uncontrolled systolic hypertension
    Lacourciere, Yves
    Poirier, Luc
    Lefebvre, Jean
    Ross, Stuart A.
    Leenen, Frans H.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 (08) : E313 - E319